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Abstract
Objectives
To investigate the safety of ofatumumab retreatment in rheumatoid arthritis.
Methods
Patients with active rheumatoid arthritis participating in two phase III trials (OFA110635 and
OFA110634) and a phase II extension trial (OFA111752) received individualised open-label
ofatumumab retreatment (700 mg X 2 intravenous infusions two weeks apart)24 weeks
following the first course and16 weeks following further courses. Retreatment required
evidence of clinical response followed by disease relapse. These studies were prematurely
terminated by the sponsor to refocus development on subcutaneous delivery. Due to differ-
ences in study designs and populations, data are summarised separately for each study.
Results
483 patients (243, 148 and 92 in OFA110635, OFA110634 and OFA111752 respectively)
received up to 7 treatment courses of intravenous ofatumumab; cumulative duration of
exposure was 463, 182 and 175 patient-years, respectively. Mean time between courses
was 17–47 weeks. Ofatumumab induced a profound depletion of peripheral B-lymphocytes.
Retreated patients derived benefit based on improvement in DAS28. Adverse events were
reported for 93% (226/243), 91% (134/148) and 76% (70/92), serious adverse events for
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18% (44/243), 20% (30/148) and 12% (11/92) and serious infections for 3% (8/243), 5% (7/
148) and 1% (1/92) of patients in OFA110635, OFA110634 and OFA111752, respectively.
The most common adverse events were infusion-related reactions during the first infusion
of the first course (48–79%); serious infusion-related reactions were rare (<1% [1/243], 5%
[8/148], and 1% [1/92] of patients). Two deaths occurred (fulminant hepatitis B virus infec-
tion and interstitial lung disease).
Conclusions
Ofatumumab was generally well tolerated with no evidence of increased safety risks with
multiple retreatments. Serious infections were uncommon and did not increase over time.
Trial Registration
ClinicalTrials.gov 110635
ClinicalTrials.gov 110634
ClinicalTrials.gov 111752
Introduction
The development of B-lymphocyte depletion therapy marked a significant advance in the treat-
ment of RA. In the late 1990s rituximab, a chimeric mouse-human monoclonal antibody
(mAb) selectively targeting the B-cell surface CD20 antigen, was shown to be effective in
patients with active rheumatoid arthritis (RA) [1–3]. Considerable variability in clinical
response was observed despite effective peripheral B-cell depletion, and repeated treatment
cycles were necessary to achieve sustained efficacy [4].
Ofatumumab is a human immunoglobulin G (IgG)1ĸmAb that binds to a membrane-prox-
imal epitope on the human CD20 molecule, distinct from the epitope recognised by rituximab
[5,6] and by humanised anti-CD20 mAbs like ocrelizumab [7,8], veltuzumab [9] and obinutu-
zumab [10]. Ofatumumab induces potent B-cell lysis primarily through complement-depen-
dent cytotoxicity and antibody-dependent cell-mediated cytotoxicity [6,11]. It is approved, as
an intravenous infusion, for the treatment of chronic lymphocytic leukemia [12].
A randomised, placebo-controlled phase I/II study of ofatumumab at doses of 300, 700 and
1000 mg administered as two intravenous infusions two weeks apart showed significant clinical
benefit over placebo in patients with active RA and an inadequate response to disease-modify-
ing anti-rheumatic drugs (DMARDs) [13]. The 700 mg X 2 dose (one treatment course) was
selected for further investigation in two confirmatory phase III trials in defined populations of
RA patients. Study OFA110635 enrolled only active RA patients who had never been previ-
ously administered biologic therapies (biologic-naïve) and had demonstrated an inadequate
response to methotrexate (MTX); study OFA110634 enrolled active RA patients who had failed
one or more tumour necrosis factor (TNF) antagonists. OFA111752 was an open-label ofatu-
mumab re-treatment extension study of the initial dose-ranging trial in active RA patients who
were not responding to DMARDs. A key objective of these studies was to investigate the effi-
cacy and safety of repeated treatment courses of ofatumumab administered on an individual-
ised basis (dependent upon clinical need), to active RA patients despite previous RA
treatments with either MTX, TNF-inhibitors or DMARDs.
Results of the initial dose-ranging study [13] and the 24-week, double-blind, placebo-con-
trolled period of the Phase III study in biologic-naive MTX-refractory patients [14] indicated
that the short-term efficacy and safety of intravenous ofatumumab in RA was similar overall to
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that observed with other anti-CD20 therapies [8,15]. Furthermore, consistent with the high
potency of ofatumumab, a single-blind phase I/II trial in RA patients on background MTX
demonstrated that even single subcutaneous formulation doses of ofatumumab, as low as 30
mg, were able to induce profound and persistent peripheral B-cell depletion [16]. Based on the
encouraging results of the subcutaneous study, the clinical development of the intravenous for-
mulation of ofatumumab in RA was discontinued and the three ongoing RA trials were prema-
turely terminated in favour of initiating a clinical development programme to evaluate the
effects of subcutaneously administered ofatumumab in autoimmune diseases instead.
This article reports the long-term safety and efficacy data obtained following repeated treat-
ment cycles of intravenous ofatumumab from the three terminated clinical trials in RA
patients. Due to differences in study designs and patient populations, data are summarised sep-
arately for each study and have not been pooled.
Material and Methods
Study designs and patients
The protocols for the three clinical trials included in this article and the CONSORT checklist are
available as supporting information (S1 Protocol; S2 Protocol; S3 Protocol and S1 CONSORT
Checklist).
OFA110635 and OFA110634 (ClinicalTrials.gov identifiers NCT00611455 and
NCT00603525, respectively) were Phase III trials with a 24-week randomised, placebo-con-
trolled double-blind (DB) period, a 120-week open-label (OL) retreatment period and a safety
follow-up (FU) of up to two years. OFA111752 (ClinicalTrials.gov identifier NCT00655824)
was a Phase II extension trial with a 130-week OL period and safety FU, in patients who had
received ofatumumab (300, 700 or 1000 mg) or placebo in a preceding Phase I/II dose-ranging
trial [13] (Table 1). The trials were conducted between January 2008 and July 2013. Ethical
approval was obtained from the independent ethics committee or institutional review board
for each participating site and all patients provided written informed consent. Key inclusion/
exclusion criteria for each trial are summarised in Table 1.
Also excluded were patients with chronic or ongoing active infectious disease requiring sys-
temic treatment such as, but not limited to, chronic renal infection, chronic chest infection
with bronchiectasis, tuberculosis (TB) and active hepatitis B and C. In particular, patients with
a screening chest X-ray suggestive of TB without documentation of adequate TB treatment
were excluded. Screening for latent TB infection using intradermal injection of tuberculin (e.g.
the Mantoux test or equivalent) was to be conducted in accordance with local guidelines.
Patients with a positive skin tuberculin test were excluded if the investigator judged the patient
to be at risk of latent TB infection.
In studies OFA110635 and OFA110634, ofatumumab treatment course 1 was the first
course of ofatumumab the patient received, regardless of whether this occurred during the DB
period (for those patients randomised to receive DB ofatumumab) or the OL period (for those
patients randomised to receive DB placebo). In study OFA111752, ofatumumab treatment
course 1 was the first course of ofatumumab the patient received in this OL study (as some
patients had previously received a course of ofatumumab at a dose of 300, 700 or 1000 mg X 2
during the preceding Phase I/II trial). Active RA was defined according to the ACR 1987 classi-
fication criteria [17]. The swollen joint count was based on 66 joints for OFA110635 and
OFA110634 and 28 joints for OFA111752; the tender joint count was based on 68 joints for
OFA110635 and OFA110634 and 28 joints for OFA111752. Baseline DAS28 was calculated
using CRP; if CRP was missing ESR was used instead. Previous RA treatment failure was
defined as insufficient efficacy or intolerance. Patients underwent a washout period of4
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Table 1. Study Designs, Demographic and Baseline Characteristics.
OFA110635 OFA110634 OFA111752
Study design
Type of study Phase III Phase III Phase II extension
Planned duration 24-week DB period; 120-week OL perioda;
Safety FU up to 2 yrs.
24-week DB period; 120-week OL perioda;
Safety FU up to 2 yrs.
130-week OL perioda; Safety FU up
to 2 yrs.
Number of sites 36 41 17
Geographic
locations
Europe, South America, Australia Europe, South America, East Asia Europe, North America
Key inclusion and exclusion criteria
Age 18 years 18 years 18 years
Gender Male or non-pregnant female Male or non-pregnant female Male or non-pregnant female
RA disease
characteristics
Active RA for 6 months; 8 swollen and 8
tender joints (of 66/68 assessed); CRP 1.0
mg/dl or ESR 22 mm/h; DAS28-ESR 3.2
Active RA for 6 months; 8 swollen and 8
tender joints (of 66/68 assessed); CRP 1.0
mg/dl or ESR 22 mm/h; DAS28-ESR 3.2
Active RA for 6 months; 3 swollen
and 3 tender joints (of 28
assessed); DAS28-ESR 3.2
Previous RA
therapy
Biologic naive and failed treatment with MTX Failed treatment with TNF antagonist Failed treatment with at least one
DMARD
MTX therapy at
study entry
Required (7.5–25 mg/week for 12 weeks
and at stable dose for 4 weeks)
Required (7.5–25 mg/week for 12 weeks
and at stable dose for 4 weeks)
Not required (if on MTX had to be on
7.5–25 mg/week for 12 weeks, and
at stable dose for 4 weeks)
IgG LLN LLN LLN
Demographic and baseline characteristics
N 260 169 92
Mean (SD) age,
years
52.7 (11.39) 53.5 (12.67) 52.9 (10.73)
Female, n (%) 214 (82) 140 (83) 84 (91)
Race, n (%)
White 253 (97) 135 (80) 92 (100)
Asian 1 (<1) 32 (19) 0
African American/
African
1 (<1) 0 0
Other 5 (2) 2 (1) 0
Mean (SD)
disease duration,
yrs
8.51 (8.174) 12.8 (9.08) 12.7 (8.95)
Concomitant MTX,
n (%)
260 (100) 169 (100) 87 (95)
RF positive, n (%) 219 (84) 124 (73) 79 (86)
Anti-CCP positive,
n (%)
224 (86) 137 (81) 80 (87)
Mean (SD) swollen
joint count
15.9 (7.14) 16.4 (7.90) 11.2 (5.22)
Mean (SD) tender
joint count
27.6 (13.00) 28.0 (13.29) 15.5 (6.45)
Mean (SD)
DAS28-CRP
5.7 (0.80) 5.9 (0.96) 5.8 (0.95)
DB, double-blind; FU, follow-up; LLN, lower limit of normal; OL, open-label.
aIn OFA110635 and OFA110634, ofatumumab treatment course 1 was the first course of ofatumumab the patient received, regardless of whether this
occurred during the DB period (for those patients randomised to receive DB ofatumumab) or the OL period (for those patients randomised to receive DB
placebo). In OFA111752, ofatumumab treatment course 1 was the first course of ofatumumab the patient received in OFA111752 (some patients had
previously received a course of ofatumumab at a dose of 300, 700 or 1000 mg in the preceding Phase I/II trial).
doi:10.1371/journal.pone.0157961.t001
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weeks for DMARDs (leflunomide 12 weeks or administration of cholestyramine according to
manufacturer’s instructions) but maintained their concomitant stable MTX therapy.
In the OL period of each trial, eligible patients received repeated ofatumumab courses (two
700 mg intravenous infusions administered two weeks apart) at individualised intervals, fol-
lowing premedication with oral antihistamine, oral paracetamol and intravenous methylpred-
nisolone [14]. In order to avoid retreating patients who may not be responsive to B-cell
depleting therapy patients were eligible to receive further ofatumumab treatment, per protocol,
only if they had demonstrated an efficacy response, defined as achieving at least a moderate
European League Against Rheumatism [EULAR] response and/or20% improvement in both
swollen and tender joint counts compared to baseline, at least once within 24 weeks from the
previous treatment course which was followed by a worsening in disease activity defined as
achieving a Disease Activity Score based on erythrocyte sedimentation rate [DAS28-ESR]3.2
plus a0.6 increase in DAS28-ESR compared to the lowest DAS28-ESR after the previous
treatment course and/or a20% increase in both tender and swollen joint counts compared to
lowest joint counts since the previous treatment course. Breakthrough pain management with
analgesics, non-steroidal anti-inflammatory drugs and one intra-articular corticosteroid injec-
tion in one joint per 6-month period was allowed. The use of other DMARDs (except for
MTX) was prohibited; however, patients in studies OFA110635 and OFA110634 who did not
achieve a clinical response were allowed non-biologic DMARD rescue treatment from week 16
of the DB phase, but this precluded their entry into the OL retreatment period of the trials. In
addition, patients with a circulating IgG level below the lower limit of normal (LLN), as mea-
sured by a central laboratory, at any time after the second ofatumumab treatment course were
withdrawn from further retreatment. Patients were evaluated every 8 weeks and the minimum
interval between retreatments was 16 weeks.
Patients who completed the OL period or who did not qualify for retreatment entered a
safety FU and were monitored every 12 weeks until their B-cells and circulating IgG levels had
returned to normal or baseline values, or for a maximum of 2 years. During the FU period RA
therapy was prescribed at each investigator’s discretion based on the patient’s clinical need and
local practice, but if treatment with another B-cell depleting agent was initiated the patient was
to be withdrawn from the trial.
Assessments
DAS28-ESR (measured at local laboratory) and DAS28 based on C-reactive protein
(DAS28-CRP) (measured at central laboratory) were assessed at each visit during the DB and
OL periods; DAS28-ESR was used by investigators to determine if patients met the criteria for
retreatment. Adverse events (AEs) were recorded during DB and OL periods; serious adverse
events (SAEs) only were to be recorded during FU. Infusion-related reactions (IRRs) occurring
during and up to 24 h after completion of each infusion (and likely to represent clinical signs
and symptoms characteristic of infusion reactions) were identified by a Safety Review Team;
serious IRRs were those that met the definition of a SAE. Although progressive multifocal leu-
koencephalopathy (PML) occurs very rarely in RA patients treated with rituximab [18],
patients were monitored throughout the trials by neurological questionnaire and plasma JC
virus DNA testing.
Blood and urine samples were collected at regular intervals for haematology, clinical chem-
istry, immunoglobulins, biomarkers (OFA110635 and OFA111752 only), virology [plasma JC
virus by PCR, hepatitis B virus (HBV) and hepatitis C virus (HCV) serology; positivity at
screening was exclusionary] and urinalysis. In OFA110635 and OFA110634 CD19+, CD3+,
CD4+ and CD8+ lymphocytes were measured by fluorescence-activated cell sorting. In
Safety of Ofatumumab in Rheumatoid Arthritis
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OFA111752, anti-ofatumumab antibodies were measured by validated enzyme-linked immu-
nosorbent assay; positive samples were further characterised (including testing for the presence
of neutralising antibodies).
Statistical methods
Data are summarised descriptively for each study, by ofatumumab treatment course. No statis-
tical tests were conducted. The randomised population (OFA110635 and OFA110634 only)
comprised all patients who received at least one infusion of study drug during the DB period.
The ofatumumab population for each study comprised all patients who received at least one
ofatumumab infusion; this is the primary population used for reporting safety and efficacy
data. The FU population comprised all patients who underwent at least one safety assessment
during the FU period.
For OFA110635 and OFA110634, baseline for the OL period was defined as the latest value
recorded prior to the first infusion of study drug in the DB period. Ofatumumab treatment
course 1 was the first course of ofatumumab the patient received, regardless of whether this
occurred during the DB period (for those patients randomised to receive DB ofatumumab) or
the OL period (for those patients randomised to receive DB placebo).
For OFA111752, baseline was defined as the latest value recorded on or before the date of
the first infusion of ofatumumab in this extension study. Ofatumumab treatment course 1 was
defined as the first course of ofatumumab the patient received in OFA111752 even though
some patients had received a course of ofatumumab at a dose of 300, 700 or 1000 mg in the pre-
ceding dose-ranging trial [13]. For FU safety monitoring, baseline values for B-cells and IgG
were the latest value recorded on or before the date of the first infusion of study drug in the pre-
ceding Phase I/II trial [13].
Time to retreatment was defined as the interval between the first infusion (infusion A) of
treatment course n and infusion A of treatment course n+1. Disease remission was defined as
DAS28 score<2.6 at any time during the treatment course and low disease activity was defined
as DAS28 score2.6 and<3.2 at any time during the treatment course. The overall duration
of exposure for a patient to ofatumumab was defined as the time between the first infusion and
completion/withdrawal from their final treatment course. The duration of exposure within a
treatment course was defined as the time from start of the first infusion for that treatment
course and the time of retreatment or withdrawal/completion.
AEs were coded using the Medical Dictionary for Regulatory Activities (MedDRA) (version
16 in OFA110635 and OFA110634; version 13 in OFA111752) and categorised by system
organ class (SOC) and preferred term. Infections and neoplasms were those events reported
within the SOCs of “Infections and infestations” and “Neoplasms (benign, malignant and
unspecified, including cysts and polyps)”, respectively.
Results
Patient population
Overall, 483 RA patients received at least one infusion of ofatumumab across the three studies
(243, 148 and 92 in OFA110635, OFA110634 and OFA111752, respectively) (Fig 1) and 364
patients (198, 93 and 73 patients, respectively) received more than one individualised treatment
course, up to a maximum of seven courses. The cumulative duration of exposure to ofatumu-
mab in each study was 463, 182 and 175 patient-years, respectively. The most common reason
for patient withdrawal was premature study termination by the sponsor (Fig 1).
Demographic and baseline characteristics were generally similar across the studies
(Table 1), except that OFA110634 was the only trial to enrol Asian (Korean) patients (24
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patients, 19%). Mean disease duration was lower, as expected, in the biological-naive MTX-
refractory trial OFA110635 compared to OFA110634 and OFA111752 (8.5, 12.8 and 12.7
years, respectively). Most patients were women (83–91%), Rheumatoid Factor (RF) positive
(73–86%) and anti-Cyclic Citrullinated Peptide antibody (anti-CCP) positive (81–87%), with a
mean age of 53 years. All patients in OFA110635 and OFA110634 and 95% of patients in
OFA111752 received concomitant MTX therapy.
Time to ofatumumab retreatment
Following the initial course of ofatumumab a decreasing number of patients needed to be
retreated (Table 2), as retreatment depended on each patient’s personal clinical need as defined
in the Methods’ section. It is important to note, however, that due to the early termination of
these studies by the sponsor, patients recruited later in the trials were withdrawn prematurely,
possibly resulting in an underestimation of treatment cycles required for disease control until
study end. Table 2 shows the mean time which occurred between treatment courses, this ran-
ged from 17 to 47 weeks. There seemed to be a tendency to shorter intervals between later
Fig 1. Flow Diagram of Patient Disposition in Each Study. The diagram shows the numbers of patients who were enrolled/randomized, received at least
one infusion of ofatumumab, completed/discontinued, and included in analysis populations in each of the three studies. DB, double-blind treatment period;
OL, open-label treatment period; FU, safety follow-up.
doi:10.1371/journal.pone.0157961.g001
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ofatumumab retreatments as B-lymphocytes seemed to repopulate earlier in patients requiring
several treatment courses.
When considering safety and efficacy data obtained from later treatment courses the small
number of patients should also be noted and the corresponding data interpreted with caution.
Overall safety profile
The majority of patients experienced at least one AE across the three ofatumumab studies: 93%
(226/243) in OFA110635, 91% (134/148) in OFA110634, and 76% (70/92) in OFA111752;
these AEs were mainly due to IRRs occurring during the first ofatumumab infusion (see
Table 3, Table 4 and Table 5 for OFA110635, OFA110634 and OFA111752 respectively). AEs
leading to trial discontinuation were reported overall for 12% (29/243), 16% (24/148) and 3%
(3/92) of patients. SAEs were reported overall for 18% (44/243), 20% (30/148) and 12% (11/92)
of patients in study OFA110635, OFA110634 and OFA111752; SAEs leading to trial discontin-
uation were reported for 4% (9/243), 6% (9/148) and 1% (1/92) of patients, respectively. Most
of the SAEs leading to discontinuation in studies OFA110634 (6/9 patients) and OFA111752
(1/1 patient) were serious IRRs, whereas only one of the SAEs leading to discontinuation in
study OFA110635 was a serious IRR (1/9 patients).
The frequencies of adverse events reported in the placebo and ofatumumab groups during
the double-blind periods of studies OFA110635 and OFA110634 are provided as supporting
information (S1 and S2 Tables).
Infusion-related reactions
IRRs represented the most common AEs overall, occurring with higher incidence on the day of
the first infusion of the first ofatumumab treatment course, consistently across the three trials
(Tables 3–5). IRRs reported on the day of the second infusion decreased considerably and
became less frequent with subsequent treatment courses. The most common symptoms were
Table 2. Time to Retreatment in Weeks by Ofatumumab Treatment Course in Each Study.
Ofatumumab Treatment Course
1 2 3 4 5 6 7
OFA110635 N = 243 N = 198 N = 136 N = 72 N = 31 N = 11 N = 2
Number retreated 198 136 72 31 11 2 0
Mean (SD) 34.3 (15.8) 34.5 (15.2) 28.8 (10.7) 20.8 (7.0) 19.9 (5.4) 17.9 (0.4) NA
Median (min, max) 30.2 (16.0, 97.3) 31.9 (16.0, 85.4) 28.0 (16.0, 58.1) 16.9 (16.0, 40.0) 17.0 (16.0, 31.9) 17.9 (17.6, 18.1) NA
OFA110634 N = 148 N = 93 N = 63 N = 30 N = 13 N = 6 -
Number retreated 93 63 30 13 6 0
Mean (SD) 32.8 (12.0) 28.6 (11.1) 24.6 (8.1) 23.9 (6.1) 19.1 (2.8) NA -
Median (min, max) 28.0 (16.0, 65.9) 25.0 (16.0, 65.0) 23.4 (16.0, 39.7) 23.7 (16.1, 32.9) 17.9 (16.3, 23.1) NA -
OFA111752 N = 92 N = 73 N = 53 N = 20 N = 8 N = 6 N = 2
Number retreated 73 53 20 8 4 2 0
Mean (SD) 41.6 (18.2) 47.0 (17.5) 33.7 (13.4) 22.1 (2.7) 23.1 (3.2) 17.1 (0.0) NA
Median (min, max) 36.0 (18.3, 98.3) 49.4 (18.6, 81.4) 30.1 (17.9, 60.1) 22.9 (17.9, 25.9) 22.3 (20.4, 27.4) 17.1 (17.1, 17.1) NA
Time to retreatment was defined as the interval between infusion A of treatment course n and infusion A of treatment course n+1. For each patient’s final
treatment course, the time was defined as the interval from infusion A to the date of withdrawal or completion. The minimum period allowed per protocol
before retreatment was 16 weeks, except for the first course of ofatumumab in the double-blind period of OFA110635 and OFA110634 for which the
minimum period allowed before retreatment was 24 weeks. Data from the final treatment course when patients withdrew due to early termination of the
study were not included in this analysis.
doi:10.1371/journal.pone.0157961.t002
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rash, urticaria, throat irritation, cough and pruritus. IRRs were mostly of mild-to-moderate
intensity. SAEs due to IRRs were reported more frequently in study OFA110634 which
enrolled patients with a previous exposure to biologic therapy (5% [8/148] in OFA110634 vs.
<1% [1/243] in OFA110635 and 1% [1/92] in OFA111752), and generally occurred during the
first infusion of the first treatment course (Tables 3–5).
Infections
Overall, 53% (130/243), 32% (48/148) and 43% (40/92) of patients experienced an infection at
any time in study OFA110635, OFA110634 and OFA111752, respectively; the percentage of
patients experiencing infections generally remained stable over time and over repeated ofatu-
mumab treatment courses (Tables 3–5). The commonly reported non-serious infections were
nasopharyngitis, upper respiratory tract infections, bronchitis, urinary tract infections and, in
Table 3. Incidence of Adverse Events by Ofatumumab Treatment Course in OFA110635.
Ofatumumab Treatment Course
1 2 3 4 5 6 7 Overall
OFA110635 N = 243 N = 198 N = 136 N = 72 N = 31 N = 11 N = 2 N = 243
Any AE 212 (87) 151 (76) 92 (68) 43 (60) 14 (45) 5 (45) 0 226 (93)
IRR on day of first infusion 168 (69) 110 (56) 64 (47) 22 (31) 2 (6) 2 (18) 0 191 (79)
IRR on day of second infusion 7 (3) 2 (1) 1 (<1) 2 (3) 0 1 (9) 0 11 (5)
AE leading to discontinuation of investigational product/withdrawal 15 (6) 4 (2) 6 (4) 4 (6) 0 0 0 29 (12)
Any SAE (fatal or non-fatal) 14 (6) 19 (10) 12 (9) 4 (6) 1 (3) 0 0 44 (18)
Serious IRR 1 (<1) 0 0 0 0 0 0 1 (<1)
SAE leading to discontinuation of investigational product/withdrawal 2 (<1) 3 (2) 3 (2) 1 (1) 0 0 0 9 (4)
Death 1 (<1) 0 1 (<1) 0 0 0 0 2 (<1)
Any infection 75 (31) 68 (34) 31 (23) 13 (18) 6 (19) 2 (18) 0 130 (53)
Most common infections (5% overall)
Nasopharyngitis 15 (6) 13 (7) 4 (3) 2 (3) 2 (6) 1 (9) 0 34 (14)
Urinary tract infection 15 (6) 10 (5) 3 (2) 4 (6) 1 (3) 1 (9) 0 27 (11)
Upper respiratory tract infection 11 (5) 7 (4) 2 (1) 0 0 0 0 20 (8)
Bronchitis 4 (2) 11 (6) 5 (4) 0 0 0 0 18 (7)
Pharyngitis 6 (2) 4 (2) 5 (4) 0 1 (3) 0 0 14 (6)
Any serious infection 3 (1) 2 (1) 2 (1) 1 (1) 0 0 0 8 (3)
Diverticulitis 0 0 0 1 (1) 0 0 0 1 (<1)
Endometritis 0 1 (<1) 0 0 0 0 0 1 (<1)
Hepatitis B 0 0 1 (<1) 0 0 0 0 1 (<1)
Lower respiratory tract infection 1 (<1) 0 0 0 0 0 0 1 (<1)
Pertussis 0 0 1 (<1) 0 0 0 0 1 (<1)
Pneumonia 1 (<1) 0 0 0 0 0 0 1 (<1)
Pyelonephritis acute 0 1 (<1) 0 0 0 0 0 1 (<1)
Tooth infection 1 (<1) 0 0 0 0 0 0 1 (<1)
Any neoplasm 0 2 (1) 1 (<1) 2 (3) 0 0 0 5 (2)
Any serious malignant neoplasm 0 1 (<1) 1 (<1) 1 (1) 0 0 0 3 (1)
AE, adverse event; IRR, infusion-related reaction; SAE, serious adverse event. Incidences are expressed as number (%) of patients with each type of
event. Percentages are based on the number of patients who received at least one infusion of ofatumumab for the respective treatment course.
Ofatumumab treatment course is the course that the patient was receiving at the onset of the event. Infections were those events reported in the MedDRA
System Organ Class of “Infections and infestations”. Neoplasms were those events reported in the MedDRA System Organ Class of “Neoplasms (benign,
malignant and unspecified, including cysts and polyps)”.
doi:10.1371/journal.pone.0157961.t003
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study OFA110634, gastroenteritis. Overall, 3% (8/243), 5% (7/148) and 1% (1/92) of patients
experienced serious infections in OFA110635, OFA110634 and OFA111752, respectively. No
cases of tuberculosis were reported even from sites in countries with high prevalence of tuber-
culosis (at the time these trials recruited patients) such as Peru, Argentina, Republic of Korea,
Russian Federation, Poland and Romania. No PML case was reported and opportunistic infec-
tions were very rare.
No cases of HBV reactivation occurred. A single case of de novo fulminant hepatitis B,
which was fatal and assessed as related to study drug by the investigator, occurred in
OFA110635 after the third ofatumumab retreatment. This 54-year-old Hungarian woman, bio-
logic-naïve and concurrently treated with oral MTX (20 mg, weekly), tested consistently nega-
tive for HBsAg, HBV surface antibody, HBV core antibody and HCV at study entry and up to
the fulminant onset of HBV infection. The genotype “D” of the HBV isolated from this patient
had both precore (G1896A) and basal core promoter mutations (A1762T and G1764A) which
are associated with a high incidence of fulminant outcome. Whether ofatumumab contributed
Table 4. Incidence of Adverse Events by Ofatumumab Treatment Course in OFA110634.
Ofatumumab Treatment Course
1 2 3 4 5 6 7 Overall
OFA110634 N = 148 N = 93 N = 63 N = 30 N = 13 N = 6 N = 0 N = 148
Any AE 127 (86) 60 (65) 37 (59) 17 (57) 8 (62) 5 (83) - 134 (91)
IRR on day of first infusion 101 (68) 48 (52) 18 (29) 10 (33) 2 (15) 1 (17) - 110 (74)
IRR on day of second infusion 1 (<1) 2 (2) 0 3 (10) 0 0 - 6 (4)
AE leading to discontinuation of investigational product/withdrawal 21 (14) 1 (1) 1 (2) 0 1 (8) 0 - 24 (16)
Any SAE (fatal or non-fatal) 20 (14) 10 (11) 2 (3) 1 (3) 0 0 - 30 (20)
Serious IRR 8 (5) 1 (1) 0 0 0 0 0 8 (5)
SAE leading to discontinuation of investigational product/withdrawal 8 (5) 0 1 (1) 0 0 0 - 9 (6)
Death 0 0 0 0 0 0 - 0
Any infection 30 (20) 20 (22) 12 (19) 4 (13) 3 (23) 3 (50) - 48 (32)
Most common infections (5% overall)
Gastroenteritis 4 (3) 3 (3) 1 (1) 0 1 (8) 0 - 9 (6)
Urinary tract infection 4 (3) 4 (4) 2 (3) 0 0 0 - 9 (6)
Bronchitis 3 (2) 1 (1) 0 3 (10) 0 0 - 7 (5)
Nasopharyngitis 6 (4) 2 (2) 1 (1) 0 0 0 - 7 (5)
Any serious infection 2 (1) 5 (5) 0 0 0 0 - 7 (5)
Urinary tract infection 1 (<1) 1 (1) 0 0 0 0 - 2 (1)
Cellulitis 0 1 (1) 0 0 0 0 - 1 (<1)
Gastroenteritis 0 1 (1) 0 0 0 0 - 1 (<1)
Herpes oesophagitis 0 1 (1) 0 0 0 0 - 1 (<1)
Oesophageal candidiasis 0 1 (1) 0 0 0 0 - 1 (<1)
Oral candidiasis 1 (<1) 0 0 0 0 0 - 1 (<1)
Respiratory tract infection 0 1 (1) 0 0 0 0 - 1 (<1)
Any neoplasm 3 (2) 1 (1) 0 0 0 0 - 3 (2)
Any serious malignant neoplasm 0 0 0 0 0 0 0 0
AE, adverse event; IRR, infusion-related reaction; SAE, serious adverse event. Incidences are expressed as number (%) of patients with each type of
event. Percentages are based on the number of patients who received at least one infusion of ofatumumab for the respective treatment course.
Ofatumumab treatment course is the course that the patient was receiving at the onset of the event. Infections were those events reported in the MedDRA
System Organ Class of “Infections and infestations”. Neoplasms were those events reported in the MedDRA System Organ Class of “Neoplasms (benign,
malignant and unspecified, including cysts and polyps)”.
doi:10.1371/journal.pone.0157961.t004
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to the fulminant course, through potentially diminishing the humoral immune response to
acute HBV infection following sustained B-cell depletion in this patient remains unclear.
Neoplasms
Overall,2% of patients had a benign or malignant neoplasm across the studies (Tables 3–5).
Serious malignant neoplasms were reported for 3 (1%) patients in OFA110635: a grade 3B-cell
lymphoma developed in a 53 year old woman after ofatumumab treatment course 4; a gingival
cancer in a 61 year old man after ofatumumab treatment course 2, and an ovarian cancer in a
56 year old woman after treatment course 3. No metastases or fatalities occurred. Other
reported neoplasms were benign.
Deaths
There were no deaths in studies OFA110634 and OFA111752. In study OFA110635 two
patients had a fatal SAE while on ofatumumab treatment: interstitial lung disease (during the
first treatment course, not considered by the investigator to be related to study drug) and the
aforementioned fulminant HBV infection. In addition, three fatal SAEs occurred during the
safety follow-up period of study OFA110635: acute pyelonephritis, cerebrovascular disorder
and pancreatic necrosis; none of these SAEs were considered by the investigators to be related
to ofatumumab.
Table 5. Incidence of Adverse Events by Ofatumumab Treatment Course in OFA111752.
Ofatumumab Treatment Course
1 2 3 4 5 6 7 Overall
OFA111752 N = 92 N = 73 N = 53 N = 20 N = 8 N = 6 N = 2 N = 92
Any AE 49 (53) 45 (62) 26 (49) 8 (40) 3 (38) 1 (25) 0 70 (76)
IRR on day of first infusion 29 (32) 20 (27) 13 (25) 4 (20) 1 (13) 0 0 42 (46)
IRR on day of second infusion 2 (2) 0 2 (4) 0 0 0 0 4 (4)
AE leading to discontinuation of investigational product/ withdrawal 3 (3) 0 0 0 0 0 0 3 (3)
Any SAE (fatal or non-fatal) 7 (8) 4 (5) 0 0 0 0 0 11 (12)
Serious IRR 1 (1) 0 0 0 0 0 0 1 (1)
SAE leading to discontinuation of investigational product/withdrawal 1 (1) 0 0 0 0 0 0 1 (1)
Death 0 0 0 0 0 0 0 0
Any infection 18 (20) 24 (33) 10 (19) 5 (25) 2 (25) 0 0 40 (43)
Most common infections (5% overall)
Upper respiratory tract infection 5 (5) 6 (8) 5 (9) 1 (5) 0 0 0 14 (15)
Rhinitis 4 (4) 1 (1) 0 1 (5) 1 (13) 0 0 5 (5)
Urinary tract infection 1 (1) 3 (4) 1 (2) 1 (5) 0 0 0 5 (5)
Any serious infection 0 1 (1) 0 0 0 0 0 1 (1)
Pneumonia 0 1 (1) 0 0 0 0 0 1 (1)
Any neoplasm 0 0 0 0 0 0 0 1 (1)a
Any serious malignant neoplasm 0 0 0 0 0 0 0 0
AE, adverse event; IRR, infusion-related reaction; SAE, serious adverse event. Incidences are expressed as number (%) of patients with each type of
event. Percentages are based on the number of patients who received at least one infusion of ofatumumab for the respective treatment course.
Ofatumumab treatment course is the course that the patient was receiving at the onset of the event. Infections were those events reported in the MedDRA
System Organ Class of “Infections and infestations”. Neoplasms were those events reported in the MedDRA System Organ Class of “Neoplasms (benign,
malignant and unspecified, including cysts and polyps)”.
aOne neoplasm in OFA111752 could not be assigned to a treatment course as the start date was not recorded.
doi:10.1371/journal.pone.0157961.t005
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Pregnancies
One unplanned pregnancy was reported in OFA110635 and two were reported in OFA110634.
The outcomes were a blighted ovum/spontaneous abortion (unrelated to ofatumumab) in
OFA110635, an elective termination and a healthy infant, respectively, in OFA110634.
Laboratory findings
Following the first infusion of ofatumumab, peripheral B-lymphocytes (CD19+) were greatly
reduced relative to pre-study (Fig 2). Retreatment was based on clinical response rather than
on B-cell counts, and peripheral B-lymphocytes were still depleted in most patients at the time
they needed retreatment. However, there was a tendency for B-lymphocytes to start repopulat-
ing earlier with increasing number of treatment courses in those patients who required multi-
ple retreatments (Fig 2). No changes in peripheral CD3+, CD4+ or CD8+ T-cell counts were
noted.
In OFA110635, the proportion of patients with a B-lymphocyte stimulator (BLyS) value
above the upper limit of normal increased from 6% (12/203) at baseline to 65% (84/130) at
week 8 and 75% (114/152) at week 24 of treatment course one. Similar results were observed in
OFA111752, with 13% (12/92) of patients having raised BLyS levels at baseline, 62% (54/87) at
week 8 and 65% (48/74) at week 24 of treatment course 1.
IgG values<LLN at some time during treatment were reported for 9% (23/243), 4% (6/148)
and 10% (9/92) of patients in OFA110635, OFA110634 and OFA111752, respectively. There
did not appear to be a pattern for the association of infections and low IgG levels. However, per
protocol patients with IgG levels falling below LLN at any time during the retreatment period
could not receive further ofatumumab courses and proceeded to the safety FU phase.
Grade 3 or 4 neutropenia, i.e. neutrophils<1,000 to 500/mm3 or neutrophils<500/mm3
respectively based on the National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI-CTCAE), was reported for 3% (7/243),<1% (1/148) and 3% (3/92) of
patients in OFA110635, OFA110634 and OFA111752, respectively; one of these patients (in
OFA110635) had a temporally associated non-serious infection of nasopharyngitis. Grade 3
thrombocytopenia, i.e. platelets<50,000 to 25,000/mm3, was reported for 1 (<1%) patient in
OFA110634.
In OFA111752 all 92 patients tested were negative for ofatumumab drug-induced
antibodies.
Clinical response
Patients who were retreated derived benefit as shown by an improvement in DAS28-ESR. The
percentage of patients who achieved disease remission or low disease activity (excluding data
for treatment courses where the number of patients was<10) ranged from approximately 30–
55% in OFA110635, 15–40% in OFA110634, and 20–45% in OFA111752, and remained rela-
tively stable across treatment courses (Fig 3 and S3 Table).
Discussion
The main goal of the clinical development of ofatumumab in RA was to optimise B-cell deple-
tion therapy by administering a human anti-CD20 mAb in order to achieve sustained efficacy
with higher disease remission rates over time and potentially improve patient safety. The suc-
cess of this therapeutic approach relied on the ability to induce lasting efficacy without expos-
ing patients to undue safety risks potentially caused by prolonged immunodeficiency. The
question of greatest importance and uncertainty, when these trials were designed, was whether
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the persistent absence of circulating B-lymphocytes would lead to a clinically significant immu-
nodeficiency with increased risk of developing serious infections or malignancies. Another
issue was establishing the correct timing for retreatment, and whether a fixed retreatment regi-
men every 6 months or a more flexible approach based on clinical need would provide the opti-
mal benefit/risk paradigm.
Fig 2. Median CD19+ B-cell Counts by Ofatumumab Treatment Course. Line plots showmedian B-cell CD19+ (GI/L) counts by week for each
treatment course in OFA110635 (panel A) and OFA110634 (panel B). The data for OFA111752 were incomplete and have not been plotted. Inf. A,
infusion A, was the first infusion of each treatment course; LLN, lower limit of normal = 0.11 GI/L; Trt, treatment.
doi:10.1371/journal.pone.0157961.g002
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Data obtained from the open-label retreatment periods of the ofatumumab RA trials show
that B-cell depletion therapy administered on clinical need is effective and generally safe in a
clinical trial setting. Previously reported data from the double-blind and placebo-controlled
phases of these trials highlighted higher rates of mild-to-moderate first dose IRRs observed
with a single course of ofatumumab (despite steroid premedication) [13,14] compared to other
intravenously administered anti-CD20s. In the current analysis of multiple treatment courses,
Fig 3. Summary of Disease Remission and Low Disease Activity Based on DAS28-ESR. Bars show the
percentage of patients who achieved disease remission (DAS28-ESR <2.6; shaded portion of each bar) or
low disease activity (DAS28-ESR2.6 to <3.2; non-shaded portion of each bar) by ofatumumab treatment
course in OFA110635 (panel A), OFA110634 (panel B) and OFA111752 (panel C).
doi:10.1371/journal.pone.0157961.g003
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first dose IRRs occurred at higher rate in patients previously exposed to a biologic DMARD in
study OFA110634. However, the number of IRRs was low and the overall benefit/risk profile of
ofatumumab remained generally favourable.
Opportunistic infections occurred rarely. Patients were closely monitored for signs of PML,
a fatal opportunistic infection caused by the JC virus in immunocompromised patients, and no
cases were reported. A study examining the aggregate experience of PML reported in associa-
tion with autoimmune rheumatic diseases (ARDs) in the FDA Adverse Event Reporting Sys-
tem database [18] revealed 14 confirmed cases of PML in ARDs patients treated with
rituximab, six of whom received rituximab for the treatment of RA.
Overall, serious infections were reported in5% of patients across multiple ofatumumab
retreatments. This was consistent with previous analyses on the long-term safety of rituximab
retreatment across multiple RA populations [19,20]. The incidence of infections of any kind
reported with rituximab in the international literature is 40% and it is similar to placebo in clin-
ical trials of at least 6 months duration; serious infections in rituximab clinical trials have ran-
ged between 2 and 7%, similar to placebo groups [21]. In our three clinical trials of
ofatumumab in RA, serious infections were similar, ranging between 1 and 5%. In contrast,
clinical trials of ocrelizumab, a humanised anti-CD20 mAb, in RA were prematurely termi-
nated by the sponsor due to an increased incidence of serious infections which occurred at the
highest, 500 mg X 2, dose tested [22]; this prompted termination of the clinical development of
ocrelizumab in RA. In particular, patients recruited in Asia (Japan) showed a higher risk of
developing serious infections [23] compared to patients recruited outside of Asia. This ten-
dency was not observed in the ofatumumab RA programme where duration of drug exposure
was longer than in the ocrelizumab programme but recruited a minority of Asian patients
from Korea (24 patients,19%) only in study OFA110634. Apart from one serious case of gastro-
enteritis, during ofatumumab treatment course two, no other serious infections occurred in
Asian patients. No cases of HBV reactivation were reported; however, the role played by
repeated ofatumumab treatments in the de novo fatal case of fulminant hepatitis B in a Hungar-
ian patient, the only case reported across the entire RA programme, remains unclear. Preva-
lence of HBV infection (HBsAg) in Hungary is reportedly low at<0.5% [24]; however, this
may be an under-estimate as high-risk groups and migrants are often under-represented. In
the rituximab REFLEX trial [25] one SAE of de novoHBV infection was reported after a single
treatment course which resolved without sequelae. Isolated cases of reactivation of hepatitis B
(including occult hepatitis B infection) are reported in RA patients receiving rituximab in the
literature [26–28]. None of these cases came from high prevalence areas such as Asian coun-
tries. In the Autoimmunity and Rituximab (AIR) Registry, which provides to our knowledge
the largest registry of infections in RA patients treated with rituximab, 1,303 patients were
treated with 1000 mg X 2 IV infusions of rituximab in French clinical practice settings [21]. Of
these, 712 patients had received retreatment at the time of the analysis: 466 with 2 cycles, 176
with 3 cycles, 45 with 4 cycles and 25 with 5 cycles. Data from the AIR registry showed a
slightly higher percentage of serious infections than what previously reported in clinical trials,
with 78 out of the 712 patients who were retreated developing 82 severe infections (11%). A
slightly higher rate of serious infections in a “real life” clinical practice setting is to be expected,
as in clinical trials several restrictions to patients’ eligibility apply. However, it is noteworthy
that overall there seems to be little evidence to date that RA patients whose B cells are persis-
tently depleted are at a significantly higher risk of developing serious infections [29–31].
Ofatumumab treatment was efficacious across distinct RA patient populations, i.e., patients
with an inadequate response to DMARDs (study OFA111752), biologic-naïve patients with an
inadequate response to MTX (study OFA110635), and patients refractory to TNF antagonists
(study OFA110634), and was able to induce low disease activity and disease remission (based
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on DAS28-ESR), as also observed previously with repeated rituximab treatment [29, 30]. Inter-
vals between treatments based on patients’ clinical need tended to be longer than 6 months in
the earlier cycles of the retreatment phase. It is important to note, however, that due to the
early termination of these studies by the sponsor, patients recruited later in the trials were with-
drawn prematurely, limiting information available on longer term treatment with
ofatumumab.
Increasingly elevated BLyS plasma levels were detected in patients administered additional
courses of ofatumumab, consistent with its function as B-cell survival factor, also in line with
rituximab data [32]. B-lymphocytes seemed to repopulate earlier in patients requiring several
retreatments. This could be explained by the increased BLyS plasma levels inducing peripheral
B-cells survival following initial depletion, by the selection of a more difficult-to-treat subpopu-
lation of RA patients, or by the development of anti-drug antibodies which may reduce ofatu-
mumab’s effectiveness.
Some important limitations of the present analysis need to be considered. Because of prema-
ture termination, OFA110634 in anti-TNF refractory patients did not enrol the planned num-
ber of patients and none of the pre-specified statistical analyses for the double-blind or open-
label periods were performed. Additionally, as the open-label period of OFA110635 and study
OFA111752 were also prematurely terminated, data have been reported using descriptive sta-
tistics only. The majority of patient withdrawals occurred because of premature trial termina-
tion by the sponsor, so it is not possible to know if those patients would have experienced
safety issues with further ofatumumab treatment courses over time. There was only limited
testing of anti-drug antibodies, therefore we are unable to confirm if repeated treatment cycles
of ofatumumab were immunogenic or not in RA patients (although the samples which were
tested were negative for anti-ofatumumab antibodies).
Conclusions
In conclusion, individualised retreatment with intravenous ofatumumab, at a dose of 700 mg X
2 infusions, was efficacious and generally safe in active RA patients with no major differences
observed across trials recruiting either biologic-naive, DMARDs-refractory, or patients previ-
ously exposed to TNF-inhibitors. Ofatumumab remains in clinical development for autoim-
mune diseases as a subcutaneous formulation.
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